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Prognostic and Mechanistic Potential of Progesterone
Sulfates in Intrahepatic Cholestasis of Pregnancy and
Pruritus Gravidarum
Shadi Abu-Hayyeh,1* Caroline Ovadia,1* TinaMarie Lieu,2 Dane D. Jensen,2 Jenny Chambers,1,3
Peter H. Dixon,1,3 Anita L€ovgren-Sandblom,4 Ruth Bolier,5 Dagmar Tolenaars,5 Andreas E. Kremer,5,6
Argyro Syngelaki,7 Muna Noori,3 David Williams,8 Jose J.G. Marin,9 Maria J. Monte,9 Kypros H. Nicolaides,7
Ulrich Beuers,5 Ronald Oude-Elferink,5 Paul T. Seed,1 Lucy Chappell,1 Hanns-Ulrich Marschall,10
Nigel W. Bunnett,2,11 and Catherine Williamson1,3
A challenge in obstetrics is to distinguish pathological symptoms from those associated
with normal changes of pregnancy, typified by the need to differentiate whether gesta-
tional pruritus of the skin is an early symptom of intrahepatic cholestasis of pregnancy
(ICP) or due to benign pruritus gravidarum. ICP is characterized by raised serum bile
acids and complicated by spontaneous preterm labor and stillbirth. A biomarker for
ICP would be invaluable for early diagnosis and treatment and to enable its differentia-
tion from other maternal diseases. Three progesterone sulfate compounds, whose con-
centrations have not previously been studied, were newly synthesized and assayed in the
serum of three groups of ICP patients and found to be significantly higher in ICP at 9-
15 weeks of gestation and prior to symptom onset (group 1 cases/samples: ICP n 5 35/
80, uncomplicated pregnancy 5 29/100), demonstrating that all three progesterone sul-
fates are prognostic for ICP. Concentrations of progesterone sulfates were associated
with itch severity and, in combination with autotaxin, distinguished pregnant women
with itch that would subsequently develop ICP from pruritus gravidarum (group 2: ICP
n 5 41, pruritus gravidarum n 5 14). In a third group of first-trimester samples all
progesterone sulfates were significantly elevated in serum from low-risk asymptomatic
women who subsequently developed ICP (ICP/uncomplicated pregnancy n 5 54/51).
Finally, we show mechanistically that progesterone sulfates mediate itch by evoking a
Tgr5-dependent scratch response in mice. Conclusion: Our discovery that sulfated pro-
gesterone metabolites are a prognostic indicator for ICP will help predict onset of ICP
and distinguish it from benign pruritus gravidarum, enabling targeted obstetric care to
a high-risk population. Delineation of a progesterone sulfate-TGR5 pruritus axis identi-
fies a therapeutic target for itch management in ICP. (HEPATOLOGY 2015; 00:000–000)
A
major challenge for obstetricians is to distin-
guish serious disorders associated with increased
maternal and fetal mortality from low-risk gesta-
tional changes. Currently, the presenting symptoms of
many obstetric syndromes are nonspecific with few early
biomarkers of serious maternal disease. We aimed to
address this problem for intrahepatic cholestasis of preg-
nancy (ICP), the commonest liver-specific disorder of
pregnancy.1 ICP is complicated by spontaneous preterm
labor, fetal distress, and intrauterine death.1,2 Early rec-
ognition of ICP is important to enable prompt treat-
ment and appropriate pregnancy surveillance. The
presenting symptom of ICP is pruritus (skin), and diag-
nosis is confirmed by demonstration of raised total
serum bile acids. However, maternal pruritus without
hepatic impairment or dermatological disorder (i.e.,
pruritus gravidarum [PG]) affects up to 25% of preg-
nant women,3,4 while ICP is much less common. It has
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a variable geographic prevalence: In the United King-
dom ICP affects 0.7% of pregnant women but is twice
as common in women of Indian or Pakistani origin,5
while in Chile it affects up to 4% of pregnant women.6
The etiology of gestational pruritus (both benign and
in ICP) is not established. Several endogenous com-
pounds have been proposed as biochemical mediators of
pruritus in ICP, including lysophosphatidic acid, a neu-
ronal activator that can act as a pruritogen, the forma-
tion of which is catalyzed by the enzyme autotaxin.7,8
These molecules are raised in the serum of women with
ICP after disease onset.8 The secondary bile acids deoxy-
cholic acid and lithocholic acid can activate the G
protein-coupled receptor TGR5 on sensory nerves to
stimulate release of itch-selective neuropeptides in the
spinal cord and evoke a Tgr5-dependent itch response
in mice.9 These results indicate that bile acids may
induce pruritus but require further evaluation in ICP as
secondary bile acids are not typically raised in the condi-
tion and concentrations of total maternal serum bile
acids do not correlate with pruritus severity.10 Although
studies of urine samples from ICP cases implicate pro-
gesterone sulfates as pruritogens,11 the precise structures
of the compounds and their capacity to cause pruritus
remain to be determined.
Sulfated progesterone metabolites contribute to the
etiology of ICP; they are partial agonists of the bile acid
receptor farnesoid X receptor (FXR)12 and competitively
inhibit hepatic bile acid uptake13 and efflux,14 resulting
in cholestasis and hypercholanemia.12 Serum concentra-
tions of progesterone sulfates are elevated in women
with ICP at 35-41 weeks of gestation,12,15 typically after
diagnosis. We hypothesized that progesterone sulfates
are raised in early pregnancy prior to the onset of ICP
and thus are potential early biomarkers that can distin-
guish ICP from benign PG. We also hypothesized that
they signal through TGR5 to mediate pruritus.
This study used three groups of ICP cases and preg-
nant controls to establish whether progesterone sulfates
are biomarker candidates for ICP diagnosis prior to
biochemical derangement and to evaluate their role
and potential mechanism of action as pruritogens
using in vitro and in vivo approaches. Our results
reveal a key role for the progesterone sulfate-TGR5
axis in ICP.
Materials and Methods
Study Approval. This study conformed to the
1975 Declaration of Helsinki guidelines; permission
was obtained from the ethics committees of Hammer-
smith Hospitals NHS Trust, London (97/5197 and 08/
H0707/21), and King’s College Hospitals NHS Trust,
London (03WH06). Written informed consent was
received from participants prior to inclusion in the
study. Murine studies were approved by the Monash
University Animal Ethics Committee.
Human Serum Samples. Serial blood samples
were collected from three prospectively recruited groups
of women with ICP, PG, or controls with uncompli-
cated pregnancies at intervals dependent upon gestation
and patient attendance. Sample preparation was as
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described.16 Three separate patient groups were used, to
ensure that results could be replicated.
Group 1 comprised 64 women: 35 opportunistically
recruited “high-risk” ICP cases with a history of choles-
tasis in a previous pregnancy and 29 with uncompli-
cated pregnancies. Women with ICP commenced
ursodeoxycholic acid (UDCA) treatment per personal
and practitioner preference following diagnosis (seven
were untreated, six were treated with UDCA, and 22
were recruited untreated and subsequently UDCA-
treated). Group 2 (the pruritus group) comprised 55
women with skin pruritus in pregnancy, 41 of whom
had pregnancies complicated by ICP (23 with previous
ICP) and 14 of whom had normal pregnancies (nine
with previous ICP); of the women who subsequently
developed ICP, 14 provided serum samples prior to the
onset of hypercholanemia (raised bile acids) but after
the onset of pruritus. Women in groups 1 and 2 were
recruited while undergoing antenatal care at the tertiary
hospitals of Imperial College London or through the
ICP Support charity. Cases were recruited between 2007
and 2014 and selected to include all cases where longitu-
dinal samples were available; 20% of ICP cases were ter-
tiary referrals (of this group 71% were referred from
specialists in different UK regions and 29% were
referred from the UK charity ICP Support).
To evaluate whether progesterone sulfate concentra-
tions reduce after delivery, we identified postnatal serum
samples from a subgroup of 12 ICP cases (due to the
limited number of postnatal samples collected) and
compared the concentration of progesterone sulfates
with the third-trimester serum sample.
Group 3 comprised 105 asymptomatic women at 11-
14 weeks’ gestation, 54 of whom later developed ICP
and 51 of whom subsequently had normal pregnancies.
Women were recruited at aneuploidy screening at King’s
College Hospital, serum samples were taken, and clini-
cal follow-up by a research midwife identified women
who developed ICP; the next sample taken from a
woman with a normal pregnancy was then used as a
control (serum analyses were incomplete due to techni-
cal error resulting in exclusion of three women with nor-
mal pregnancies).
All cases of ICP were confirmed by demonstration of
serum bile acids 10 lmol/L, and some cases also had
raised liver transaminases in association with pruritus
and no additional identifiable cause for their liver dys-
function. Exclusion criteria were other causes of hepatic
dysfunction, including preeclampsia; hemolysis, elevated
liver enzymes, and low platelets (HELLP) syndrome;
acute fatty liver of pregnancy; primary biliary cirrhosis;
active viral hepatitis; any ultrasound abnormality that
may result in biliary obstruction; and multifetal
pregnancy.
Biophysical Profiling of Participants. Details of
the participants’ relevant previous medical history, fam-
ily history, ethnicity, results of investigations, pregnancy,
and delivery were taken throughout their attendance.
Birth weight centile was calculated according to gesta-
tional age and weight at delivery17 using GROW soft-
ware (http://www.gestation.net/cc/about.htm). At the
time of serum sampling, patients with pruritus used a
horizontal visual analogue score18 (0-100 mm) to quan-
tify in millimeters the worst itch symptoms experienced
over the previous 24 hours. The marked point was
measured, and the distance in millimeters from 0 (no
itch) was converted to an itch score from 0 to 100. The
itch analogue score quantified severity of pruritus but
did not specify the physical location and extent of the
itch.
Prior to analysis, participants were grouped according
to retrospective assessment of their diagnosis of ICP at
any point during the pregnancy.
Serum Bile Acid and Progesterone Sulfate Analysis
by High-Performance Liquid Chromatography-
Tandem Mass Spectrometry. Internal standards (100
ng of d4-glycholic acid, d4-glycochenodeoxycholic acid,
d4-glycodeoxycholic acid, d4-glyco-UDCA, d4-glycoli-
thocholic acid, d4-UDCA, d4-lithocholic acid (all from
Qmx Laboratories, Essex, UK), d5-cholic acid (Toronto
Research Chemicals, Toronto, Canada), and d4-
taurocholic acid (TLC PharmaChem, Vaughan, Can-
ada), dissolved in 40 lL methanol [MeOH]) were
added to 100 lL of serum and vortexed. Acetonitrile
(800 lL) was added to precipitate proteins. After vortex-
ing and centrifugation, the supernatant was dried in a
stream of nitrogen and then first taken up in 125 lL
MeOH, followed by 125 lL of an aqueous solution
containing 40% MeOH, 0.02% formic acid, and 10
mmol/L ammonium acetate. Before injection 75 lL of
the sample was transferred to new vials and 80 lL of the
following mix was added: three parts of MeOH and one
part of an aqueous solution containing 40% MeOH,
0.02% formic acid, and 10 mmol/L ammonium acetate.
Ten microliters of this mixture was analyzed on a
high-performance liquid chromatography Alliance 2695
system coupled to a Xevo TQ mass spectrometer
(Waters, Manchester, UK) using a SunFire C18 (4.6 3
100 mm, 3.5 lm) column (Waters) and gradient elution
with 0.01% formic acid and 5 mmol/L ammonium ace-
tate in water along with 0.01% formic acid 1 5 mmol/
L ammonium acetate in MeOH as the mobile phase.
Cone voltage was 60 V and collision energy 18 eV for
unconjugated bile acids, 60 V and 29-43 eV for glycine
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conjugates, and 88 V and 56-65 eV for taurine conju-
gates, respectively. Analytes were detected using selected
ion monitoring and quantified by internal standard
methods. The desolvation temperature was 6508C, and
the source temperature was 1508C. Selected reaction
monitoring was used with dwell times of 100 ms. Analy-
tes were quantified using deuterized internal standards
except for progesterone sulfates for which d4-glyco-
UDCA was used. Results were calculated as response
(area analyte/areainternal std). Retention times and response
curves of bile acids listed (Supporting Table S1) were
evaluated from reference compounds obtained from
Sigma; 5b-pregnan-3b-ol,20-one,3-sulfate (pregnan-
diol-3-sulfate), 5a-pregnan-3a-ol,20-one,3-sulfate (allo-
pregnandiol-3-sulfate), and 5a-pregnan-3b-ol,20-one,3-
sulfate (epiallopregnandiol-3-sulfate) were obtained
from Steraloids, USA; 5b-pregnan-3a,20a-diol-3-
sulfate, 5b-pregnan-3a,20a-diol-disulfate, and 5a-
pregnan-3a,20a-diol-disulfate were from Sai Advan-
tium, India. 5a-Pregnan-3b,20a-diol-disulfate was ten-
tatively identified as the remaining isomer from its
retention times and mass spectrum. 5b-Pregnan-
3a,20a-diol-disulfate and 5a-pregnan-3a,20a-diol-
disulfate coeluted at all of the conditions tested. Using
this system, we observed less than 10% intra-assay vari-
ability when rerunning the same sample. These assays
were performed in the Department of Molecular and
Clinical Medicine, University of Gothenburg, Gothen-
burg, Sweden.
Measurement of Serum Autotaxin Activity.
Autotaxin activity was measured as described.7 Serum
was incubated with 1 mmol/L lysophosphatidylcholine
14:0, 500 mmol/L NaCl, 5 mmol/L MgCl2, 100
mmol/L Tris (pH 9.0), and 0.05% Triton X-100 for 60
minutes at 37oC. Liberated choline was detected using
choline oxidase (2 U/mL), horseradish peroxidase (1.6
U/mL), and homovanillic acid, with emitted fluores-
cence recorded using a NOVOstar analyzer. Using this
system, we observed less than 10% inter-assay and
intra-assay variance. The autotaxin assay was per-
formed at the Academic Medical Centre, Amsterdam,
The Netherlands.
Cyclic Adenosine Monophosphate Bioluminescence
Resonance Energy Transfer CAMYEL Assay. The
bioluminescence resonance energy transfer CAMYEL
(cAMP sensor using YFP-Epac-RLuc) cyclic adenosine
monophosphate (cAMP) sensor permits quantification
of intracellular cAMP concentrations with high sensitiv-
ity and a broad dynamic range19 and has been used pre-
viously to measure TGR5 signaling in cells.20 HEK293
cells that stably express the TGR5 receptor were gener-
ated using the FLP-In system (Invitrogen). The charac-
terization of these cells has been described.21 HEK293
and HEK-HA-TGR5 cells (4 3 106 per 10-cm plate)
were transfected with 4 lg of complementary DNA
(cDNA) encoding the CAMYEL sensor. Cells were
transfected using polyethylenimine with a 6:1 polyethy-
lenimine:cDNA ratio in 500 lL of 0.15 M NaCl. The
polyethylenimine:cDNA mixture was added to the cells
in the 10-cm plate, and cells were incubated overnight
in 5% CO2 at 378C in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum.
Cells were washed in phosphate-buffered saline and
incubated in 1 mL of versene for 10 minutes. Cells were
suspended in Dulbecco’s modified Eagle’s medium and
10% fetal bovine serum, plated onto poly-D-lysine-
treated 96-well plates, and incubated overnight in 5%
CO2 at 378C. To test cAMP production, cells were
washed in prewarmed Hank’s balanced salt solution and
then incubated in 80 lL Hank’s balanced salt solution
for 30 minutes at 378C. Coelenterazine (NanoLight
Technology, Pinetop, AZ; 10 lL of 10 lmol/L in
Hank’s balanced salt solution) was added, and cells were
incubated in the dark for 10 minutes at 378C. Lumines-
cence for RLuc8 (480 nm) and YFP (530 nm) was
measured using a microplate reader (PHERAstar
Omega; BMG Labtech, Mornington, Australia). A 2-
minute baseline was established before addition of the
agonists. cAMP production was measured for 10
minutes following addition of the agonists, forskolin
(10 lmol/L), or vehicle. Baseline and vehicle control
values were subtracted, and the bioluminescence reso-
nance energy transfer signal was normalized as a per-
centage of the forskolin response. This assay was
performed at Monash University, Parkville, Australia.
Scratching Behavior. Scratching behavior was
studied in mice (C57BL/6 (wild-type [WT]), Tgr5
knockout [KO], male and female, 6-10 weeks) as
described.9 The fur at the base of the neck was shaved,
and mice were placed in individual cylinders on a glass
shelf. Mice were acclimatized to the experimental room,
restraint apparatus, and investigator for 2-hour periods
on 2 successive days before experiments. After acclimati-
zation, 20 lL of 100 lmol/L 5b-pregnan-3a-20a-diol-
sulfate (PM3S) or vehicle (1% dimethyl sulfoxide) was
injected intradermally at the nape of the neck (vehicle
WT n 5 4, PM3S WT n 5 5, PM3S Tgr5-KO n 5 4).
Hind limb scratching to the injection site was video-
recorded for 120 minutes. Two observers unaware of
test agents or genotypes quantified scratching behavior.
One scratch was defined as lifting the hind limb to the
injection site and then placing the paw on the floor,
regardless of the number of strokes. If counts differed by
more than three scratches over a 30-minute period, both
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observers reevaluated the record. Results are expressed as
scratching events during 60 minutes of observation.
Transactivation Assays. Huh7 cells seeded into
96-well plates were transfected with 10.4 ng plasmid
circular DNA (pcDNA)-retinoid X receptor, 10.4 ng
pcDNA-FXRa2/pcDNA3.1 together with 10.4 ng and
40 ng pGL3-IBAP-Luc and pcDNA3.1-green fluores-
cent protein using Fugene 6 transfection reagent (Prom-
ega) at a 3:1 ratio. Twenty-four hours later, cells were
washed and treated with 0 or 50 lM compound 6 0.5
lM GW4064 (Sigma-Aldrich). After 24 hours, green
fluorescent protein activity was measured (internal con-
trol for normalization) followed by the addition of
Steadylite plus (PerkinElmer) to determine luciferase
activity, both of which were measured in a PheraStar FS
(BMG) plate reader. Transfection experiments were per-
formed three times, and the results are shown as mean
values of triplicates and standard deviations.
Statistics. For group 1, log transformations of data
were undertaken and results are presented as ratios of
the geometric mean values between groups and over
time. Results were corrected for multiple measures and
multiple markers being analyzed. Interval regression was
used for each assay.
Trend tests were performed by analyzing the random-
effects interval regression on the logged concentrations,
with interactions between patient groups and linear
effects of time.
For group 2, patient demographic group results and
visual analogue itch scores were compared using the
Mann-Whitney U test, and serial serum concentrations
of progesterone metabolites using unpaired Student t
test (Prism 6; Graphpad Software Inc.). Progesterone
metabolite concentrations were log-transformed prior
to analysis due to nonnormally distributed data. Lon-
gitudinal comparisons between disease groups of pruri-
tus scores with biochemical markers were performed
using Stata software (version 11; StataCorp, College
Station, TX). Confounding based on multiple meas-
ures and gestational effects was accounted for, and sub-
sequent linear and logistic regression analyses were
performed.
For the HEK-HA-TGR5 cAMP assays and murine
scratching assays, results are expressed as mean 6 stand-
ard error of the mean. Data were compared statistically
using Graphpad Prism 6 for multiple groups analysis of
variance and Tukey-Kramer post hoc test. P < 0.05 was
considered significant.
Table 1. Clinical and Demographic Characteristics of ICP, PG and Control Cases in Two Groups Used to Evaluate Sulfated
Progesterone Metabolites as Biomarkers
Characteristic
Group 1 Group 2
ICP (n 5 35) Control (n 5 29) P ICP (n 5 41) PG (n 5 14) P
Age (years, 6 SD) 33.4 6 4.6 30.8 6 4.8 0.02 32.7 6 4.3 35.6 6 4.3 0.01
Ethnic group, number (%)
White 22 (63) 27 (93) 0.02 25 (61) 11 (79) NS
Black 4 (11) 0 NS 4 (10) 0 NS
Asian 8 (23) 1 (3) NS 9 (22) 1 (7) NS
Other 1 (3) 1 (3) NS 3 (7) 2 (14) NS
Previous pregnancies 24 weeks, number (%)
0 0 26 (90) <0.01 11 (27) 2 (14) NS
1 20 (57) 1 (3) <0.01 18 (44) 9 (64) NS
2 15 (43) 1 (3) <0.01 11 (27) 2 (14) NS
Unknown 0 1 (3) NS 1 (2) 1 (7) NS
Gestational age at diagnosis (weeks 6 SD) 2911 6 613 n/a 3010 6 712 n/a
Severity of ICP, number (%)
Total bile acids 5 10-39.9 lmol/L 13 (37) n/a 16 (39) n/a
Total bile acids 40 lmol/L 22 (63) n/a 25 (61) n/a
Mean serum ALT, IU/L 6 SD 88.3 6 131.2 n/a 145.3 6 197.2 29.4 6 30.6
Onset of labor, number (%)
Spontaneous 5 (14) 16 (55) <0.01 7 (17) 4 (29) NS
Induced 14 (40) 8 (28) NS 24 (59) 3 (21) 0.02
Prelabor cesarean section 13 (37) 2 (7) 0.02 8 (20) 6 (43) NS
Unknown 3 (9) 3 (10) NS 2 (5) 1 (7) NS
Gestational age at delivery (weeks 6 SD) 3710 6 114 3916 6 112 <0.01 3710 6 113 3812 6 012 <0.01
Preterm delivery <37/40, number (%) 12 (34) 0 <0.01 14 (34) 2 (14) NS
Birth weight, kg 6 SD 3.1 6 0.4 3.5 6 0.4 <0.01 3.1 6 0.4 3.1 6 0.6 NS
Birth weight centile, number 6 SD 67 6 28 49 6 32 0.01 72 6 25 47 6 35 0.01
Mean serum ALT values based on levels detected in the first sample obtained from each ICP case. P value shown where a comparison resulted in statistical sig-
nificance. Values are given as means, unless otherwise stated.
Abbreviations: ALT, alanine transaminase; n/a, not applicable; NS, not significant.
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Results
Progesterone Sulfates Are Prognostic Indicators of
ICP. To establish whether progesterone sulfates can
predict women at risk of ICP in early pregnancy before
symptom onset, a group of ICP cases and uncompli-
cated pregnancy controls was used to establish gesta-
tional profiles of three sulfated progesterone metabolites
(group 1; Table 1). We obtained the following progester-
one sulfate standards, which were previously implicated
in ICP based on analysis of gas chromatograhic/mass
spectrometric spectra22,23 and all of which were synthe-
sized de novo: 5a-pregnan-3a,-20a-diol-3,20-disulfate
(PM2DiS), 5b-pregnan-3a,-20a-diol-3-sulfate (PM3S),
and 5b-pregnan-3a,-20a-diol-3,20-disulfate (PM3DiS)
(Supporting Fig. S1).
A comparison of geometric means across all gesta-
tional weeks for PM2DiS, PM3S, and PM3DiS
revealed, respectively, 4.5-fold, 2.0-fold, and 12.2-fold
significant increases in serum concentrations in
untreated ICP cases compared to pregnant controls (P
< 0.001) (Fig. 1). Importantly, concentrations of
PM2DiS, PM3S, and PM3DiS were supraphysiologi-
cally raised compared to normal pregnant controls by
10.6-fold, 1.7-fold, and 24.3-fold, respectively, at weeks
9-15 (P < 0.05), when 91% of these participants were
asymptomatic, indicating their potential as predictive
biomarkers for ICP. Concentrations of PM3S in ICP
steadily increased at a constant rate from 9 to 41 weeks,
whereas concentrations of PM3DiS and PM2DiS
increased steeply from 24 to 41 weeks for the ICP group
compared to controls (P < 0.05) (Fig. 1).
UDCA treatment improves maternal pruritus and
biochemical derangements in ICP. UDCA signifi-
cantly reduced PM2DiS and PM3DiS concentrations
relative to untreated ICP women throughout the last
trimester of pregnancy (P < 0.05). A trend analysis
showed a significant change in the trend of PM3DiS
with UDCA treatment in the third trimester of ICP
compared to the untreated ICP group (P < 0.05),
becoming similar to the pregnant control group trend
(Fig. 1).
Fig. 1. Gestational serum profiles of PM2DiS, PM3S, and PM3DiS
in group 1. Panels A, B, and C show the mean concentrations of
PM2DiS, PM3S, and PM3DiS, respectively, for serum samples obtained
at different gestational time points from women with uncomplicated
pregnancies (control, closed squares), untreated ICP (closed circles),
and UDCA-treated ICP (closed triangles). Error bars represent 6
standard error of the mean. P values for gestational week category
comparison of untreated ICP versus controls were determined by Stu-
dent t test.
Table 2. Maternal Concentrations of Progesterone Sulfates
in the Last Serum Sample Prior to Parturition and in
Subsequent Postnatal Serum Samples in ICP
Case
Gestational
Day/Postnatal Day
PM3S
(lmol/L)
PM3DiS
(lmol/L)
PM2DiS
(lmol/L)
1 GD 266 8.03 0.62 1.48
PN16 2.24 0.09 0.49
2 GD 241 2.75 1.28 1.27
PN166 0.00 0.00 0.00
3 GD 256 12.44 1.88 3.89
PN134 0.03 0.01 0.00
4 GD 255 7.22 2.19 3.30
PN112 0.04 0.03 0.09
5 GD 232 21.07 6.71 3.31
PN121 0.00 0.00 0.00
6 GD 269 2.28 0.52 1.25
PN140 0.00 0.00 0.00
7 GD 237 47.36 11.81 1.81
PN11 19.99 9.45 0.94
PN142 0.00 0.00 0.00
8 GD 261 9.85 4.76 5.94
PN140 0.02 0.00 0.00
9 GD 248 11.10 14.41 8.97
PN142 0.02 0.00 0.00
10 GD 252 20.04 5.31 4.90
PN113 3.74 3.44 1.72
11 GD 268 23.72 3.88 4.28
PN156 0.06 0.00 0.07
12 GD 255 15.64 5.60 6.04
PN11 9.29 5.15 6.00
Abbreviations: GD, gestational day; PN, postnatal.
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Progesterone Sulfate Concentrations Rapidly
Resolve in ICP Serum Following Parturition. To
establish whether progesterone sulfate concentrations
persist following parturition in ICP, concentrations of
progesterone metabolites in the last sample in ICP
cases prior to parturition and postnatal samples col-
lected thereafter were assayed in a subgroup of
patients. Concentrations of PM2DiS, PM3S, and
PM3DiS decreased rapidly following birth and nor-
malized to almost undetectable levels as early as 12
days postpartum (Table 2).
Progesterone Sulfates Are Associated With Severity
of Itch in ICP and Can Predict Its Subsequent
Onset. To assess the involvement of progesterone sul-
fates in pruritus, we investigated the relationship
between pruritus severity and serum concentrations of
progesterone metabolites in women with pregnancy-
associated pruritus (Table 1). Serum PM2DiS, PM3S,
and PM3DiS concentrations all differentiated women
with ICP from PG (P < 0.05) (Table 3). Serum concen-
trations of PM3S (odds ratio [OR] 5 6.1, 95% confi-
dence interval [CI] 0.6-11.5, P < 0.05) and autotaxin
activity (OR 5 1.4, 95% CI 0.3-2.4, P < 0.05) were
significantly associated with itch severity in ICP.
To determine whether progesterone sulfates could
predict subsequent ICP, logistic regression was per-
formed on PM2DiS, PM3S, and PM3DiS concentra-
tions and autotaxin activity, using the first serum sample
from women at presentation with pruritus and normal
serum biochemistry (Table 4). PM2DiS and PM3DiS
differentiated between the women who would subse-
quently develop ICP (P < 0.05, OR 5 2.8, 95% CI
1.5-5.2, and OR 5 2.5, 95% CI 1.2-5.4, respectively).
To refine a prediction algorithm, we evaluated
whether a combination of markers could more reliably
predict disease. PM2DiS, PM3DiS, and autotaxin in
combination resulted in an improved area under the
receiver operating characteristic (ROC) curve of 0.91
(95% CI 0.80-1.00) in contrast to autotaxin (0.73, 95%
CI 0.52-0.94), PM2DiS (0.72, 95% CI 0.52-0.92), or
PM3DiS (0.74, 95% CI 0.55-0.94) alone (Fig. 2A).
Plotting this combination as a predictive score for the
first serum sample from women presenting with PG
enabled clear differentiation between those who would
subsequently develop ICP and those who continue to
have benign PG (Fig. 2B).
Progesterone Sulfates Are Supraphysiologically Raised
in Early Gestation in Low-Risk ICP Cases. We eval-
uated this predictive algorithm in a third group of
asymptomatic pregnant women who gave serum sam-
ples at 11-14 gestational weeks for a study of serum bio-
markers to predict adverse pregnancy outcome (Table
5). Fifty-four women from this group developed ICP in
later pregnancy, and their progesterone sulfate concen-
trations were compared to those of 51 women with
uncomplicated pregnancies. PM2DiS, PM3S, and
PM3DiS concentrations were significantly raised in
women with subsequent ICP (Table 5). Autotaxin did
not predict ICP at this early gestation (area under the
curve 5 0.55, 95% CI 0.43-0.66), while PM3DiS and
PM2DiS in combination showed some predictive ability
(area under the curve 5 0.68, 95% CI 0.58-0.78) (Sup-
porting Fig. S2).
Progesterone Sulfates Signal Through TGR5 to
Mediate Itch. Activation of the G protein-coupled
receptor Tgr5 elicits an itch response in mice.9 We
therefore hypothesized that progesterone metabolites
associated with itch in ICP can activate TGR5 in vitro.
HEK cells stably transfected with TGR5 or empty vec-
tor control cells were transfected with the CAMYEL
Table 4. Autotaxin, PM2DiS, and PM3DiS All Have the Ability
to Predict ICP When Measured at the Time of Onset of
Gestational Pruritus
ICP Marker OR of Future ICP (95% CI) P Area Under ROC Curve
PM3S 1.70 (0.97-3.01) 0.07 0.45 (0.23-0.68)
PM3DiS 2.77 (1.48-5.19) <0.01 0.74 (0.55-0.94)
PM2DiS 2.54 (1.18-5.44) 0.02 0.72 (0.52-0.92)
Autotaxin 2.22 (0.99-4.86) 0.07 0.73 (0.52-0.94)
Abbreviation: ROC, receiver operating characteristic.
Table 3. Associations Between Biochemical Markers and Pruritus Scores and Their Ability to Differentiate ICP From PG
Biomarker
Association With Pruritus
ICP PG Ability to Identify ICP
Change in VAS (95% CI) P Change in VAS (95% CI) P OR (95% CI) P
PM3S 6.1 (0.6-11.5) 0.03 0.9 (24.6–6.3) NS 1.7 (1.1-2.4) 0.01
PM3DiS 2.2 (21.6–6) NS 22.5 (26.2–1.2) NS 2.1 (1.4-3.4) <0.01
PM2DiS 20.3 (25.3–4.6) NS 28.0 (214.9–1.2) 0.03 1.7 (1.2-2.5) 0.01
Autotaxin 1.4 (0.3-2.4) 0.01 2.0 (20.1–4.1) NS 2.3 (2.1-2.6) <0.01
Linear regression results showing the effect of doubling biochemical markers and change in visual analogue score for ICP and PG and ORs for developing ICP. P
value shown where a comparison resulted in statistical significance.
Abbreviations: NS, not significant; VAS, visual analogue score.
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Table 5. Maternal Characteristics of Pregnancies Assessed in a Group of Low-Risk Women Taken in the First Trimester of
Pregnancy and Their Pregnancy Outcomes, With Levels of Serum Sulfated Progesterone Metabolites in These
First-Trimester Samples
Characteristic/Marker
Group 3
ICP (n 5 54) Control (n 5 51) P
Age, years 6 SD 32 6 5.4 31 6 5.2 NS
Ethnic group, number (%)
White 42 (78) 35 (69) NS
Black 6 (11) 11 (22) NS
Asian 5 (9) 3 (6) NS
Other 1 (2) 2 (4) NS
Previous pregnancies 24 weeks, number (%)
0 28 (52) 26 (51) NS
1 22 (41) 15 (29) NS
2 4 (7) 10 (20) NS
Onset of labor, number (%)
Spontaneous 12 (22) 46 (90) <0.01
Induced 34 (63) 3 (6) <0.01
Prelabor cesarean section 8 (15) 2 (4) NS
Gestational age at delivery, weeks 6 SD 3813 6 111 4011 6 111 <0.01
Preterm delivery <37/40, number (%) 2 (4) 0 NS
Birth weight, kg 6 SD 3.3 6 0.5 3.4 6 0.3 NS
Birth weight centile, number 6 SD 60 6 30 42 6 23 <0.01
Stillbirth, number (%) 0 0
Progesterone metabolite, lmol/L mean 6 SEM
PM3S 1.4 6 0.1 1.1 6 0.1 0.02
PM3DiS 0.3 6 0 0.2 6 0 <0.01
PM2DiS 2.8 6 0.3 1.9 6 0.2 <0.01
Total bile acids, lmol/L mean 6 SEM 3.9 6 0.4 4 6 0.5 NS
Autotaxin activity, nmol/ml/min 6 SEM 12.9 6 1.2 11.6 6 1.1 NS
P value shown where a comparison resulted in statistical significance. Values given as means, unless otherwise stated.
Abbreviations: NS, not significant; SD, standard deviation; SEM, standard error of mean.
Fig. 2. Progesterone sulfates and autotaxin can predict subsequent onset of ICP in pregnant women with pruritus. The receiver operating
curves (A) improved toward an optimal area under the curve of 1.0 when biomarkers were evaluated in combination: PM2DiS 1 PM3DiS (com-
plete line), autotaxin (dashed line), and PM2DiS 1 PM3DiS 1 autotaxin (dotted and dashed line). (B) A combined predictive score (PM2DiS
1 PM3DiS 1 autotaxin) of greater than 0.25 for individual samples plotted against the gestational day of sampling reliably predicted all ICP
cases. Women who developed ICP (n 5 14, closed circles) and PG (n 5 14, open triangles) were reliably distinguished by this score; dashed
line represents demarcation between the two groups. Abbreviation: AUC, area under the curve.
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cAMP sensor and treated with the cAMP inducer for-
skolin or increasing concentrations of PM2DiS, PM3S,
and PM3DiS. In HEK-TGR5 cells, PM3S elicited a
cAMP response at concentrations of 1 lmol/L,
whereas there was no cAMP response in control cells.
PM3S stimulated a concentration-dependent formation
of cAMP with a 50% effective concentration of 5.5
lmol/L (Fig. 3A; and Supporting Fig. S3). Notably,
these PM3S concentrations were demonstrated from 20
weeks’ gestation in women with ICP (Fig. 1) and signifi-
cantly associated with pruritus severity (Table 3). In con-
trast, PM2DiS and PM3DiS stimulated cAMP
formation at extremely high concentrations. The tempo-
ral profile for the 1 lmol/L PM3S-mediated cAMP
response was consistent with the rapid actions of an acti-
vated G protein-coupled receptor (Fig. 3B). We also
excluded FXR as a possible mediator of the progesterone
sulfate signal as all three progesterone sulfates were
unable to either transactivate FXR or inhibit GW4064-
mediated FXR transactivity in an FXR-reporter assay
system (Supporting Fig. S4).
Because PM3S activates TGR5 in HEK-TGR5 cells,
we examined whether it could evoke Tgr5-mediated
scratching in mice. PM3S or vehicle (control) was intra-
dermally injected into the nape of the neck of WT and
Tgr5-KO mice, and scratching behavior was measured
for 60 minutes. In WTmice, PM3S stimulated a robust
scratching response in the first 30 minutes, which was
16-fold higher than that evoked by vehicle (P < 0.05)
(Fig. 3C) and significantly blunted by three-fold in
Tgr5-KO mice compared to WTmice (P < 0.05) (Fig.
3C). PM3S continued to stimulate scratching in WT
mice from 30 to 60 minutes, whereas the response in
Tgr5-KO mice was attenuated after 30 minutes. Cumu-
latively over the whole hour, there was a 21-fold increase
in observed scratches in the PM3S-challenged WTmice
(P < 0.05), which was significantly abrogated in the
Tgr5-KO mice (P < 0.05).
Fig. 3. Progesterone metabolites can activate TGR5 and elicit a Tgr5-mediated itch response in mice. cAMP formation was monitored over
time in HEK293 cells expressing TGR5 or control cells that were treated with 10 lmol/L of forskolin or increasing concentrations of PM3S,
PM3DiS, or PM2DiS. Data are presented as a dose response for all three compounds in both cell types (A) or time course for PM3S in TGR5-
expressing cells (B). Values represent mean 6 standard deviation of n 5 3. (C) Wild-type or Tgr5-KO mice were intradermally injected with vehi-
cle or 20 lL of 100 lmol/L PM3S, and scratching events were counted for the indicated time periods. Values represent mean 6 standard error
of the mean of n  4. *P < 0.05 for vehicle versus PM3S-administered mice scratch comparison; #P < 0.05 for PM3S WT versus PM3S Tgr5-
KO scratch comparison as determined by one-way analysis of variance. Abbreviation: BRET, bioluminescence resonance energy transfer.
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Discussion
Our results show that the sulfated progesterone
metabolites PM2DiS, PM3S, and PM3DiS are prognos-
tic for ICP as their concentrations are elevated during
early gestation when patients are asymptomatic. Fur-
thermore, UDCA treatment reduces the ICP-associated
elevation of disulfated progesterone metabolites. Inter-
estingly, concentrations of progesterone sulfates decrease
rapidly following birth, consistent with clinical reports
of rapid resolution of pruritus in ICP.24 PM3S concen-
trations were associated with the pruritus of ICP, while
all three progesterone sulfates were able to differentiate
between women with pruritus in pregnancy secondary
to ICP and those with benign PG. Combining
PM2DiS, PM3DiS, and autotaxin activity enabled pre-
diction of women who would subsequently develop ICP
when they first started itching in pregnancy, prior to ele-
vation in bile acids. Furthermore, concentrations of
PM3S consistent with ICP were capable of mediating
cAMP release in a TGR5-dependent manner and
resulted in a scratch response that was reduced in Tgr5-
KO mice.
This study has shown that PM3S is a likely pruritogen
in ICP as concentrations consistent with ICP can activate
TGR5 and mediate a Tgr5-dependent itch. Although this
result is based on a mouse model, Keitel et al. have also
shown that progesterone sulfates can modulate the activity
of TGR5 in other human tissues.25 We demonstrated
that autotaxin and progesterone sulfates are associated
with pruritus in ICP and PG, and it is likely that
autotaxin-mediated elevations in lysophosphatidic acid
cause itch through a distinct mechanism from that of pro-
gesterone sulfate-induced pruritus.
The demonstration that PM2DiS, PM3S, and
PM3DiS are significantly raised in maternal serum prior
to disease onset indicates that women with ICP are
likely to have an underlying abnormality in phase 2
metabolism (conjugation) of progesterone or phase 3
(biliary excretion) of progesterone sulfates.23 As the pro-
gesterone sulfates that are supraphysiologically raised in
ICP are agonists of the bile acid receptor TGR5, it is
possible that they impact additional downstream gesta-
tional metabolic pathways mediated by this receptor.26
These results have the potential to provide insights into
strategies to treat other cholestatic disorders complicated
by itch, e.g., primary biliary sclerosis, primary sclerosing
cholangitis, and drug-induced liver injury. They are
likely to also have a global impact as ICP is commoner
in women of South Asian and South American origin.5,6
At present there are no biomarkers for ICP in clinical
use. The potential use of the predictive score to establish
whether pregnant women with pruritus will develop
ICP is enticing and should be evaluated in future pro-
spective, well-powered studies. This is important as the
patient groups in the current study were all managed in
a single specialist center and this may have introduced
population bias. If the results are confirmed in different
populations, a feasible extension to this study would be
to assay concentrations of urinary progesterone sulfates
(Glantz et al.11) to identify a predictive score that can be
used in early pregnancy to establish whether a woman
with pruritus will develop this high-risk disease. This
could have wider clinical application with the develop-
ment of high-throughput urinary assays for progesterone
sulfates or similar laboratory tests for serum levels of
progesterone sulfates and autotaxin. This will enable
obstetricians to refer women for hospital care in a high-
risk setting or alternatively to reassure them that their
pruritus is unlikely to have pathological consequences.
In conclusion, this study describes the mechanism of
action of pruritogens that are prognostic for ICP, which
has the potential to enable obstetricians to diagnose ICP,
a common metabolic disorder of pregnancy, prior to
onset of symptoms or biochemical derangements.
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